Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470901114> ?p ?o ?g. }
- W2470901114 endingPage "1283" @default.
- W2470901114 startingPage "1283" @default.
- W2470901114 abstract "Abstract Background Activating mutations in the receptor tyrosine kinase FLT3 occur in roughly 30% of acute myeloid leukemia (AML) patients (pts), implicating FLT3 as a potential target for kinase inhibitor therapy. The multi-targeted kinase inhibitor midostaurin (PKC412) shows potent activity against FLT3 as a single agent but also in combination with intensive chemotherapy. Besides its mere presence, the allelic ratio as well as ITD insertion site within the FLT3 gene had been reported as prognostic factors in FLT3-ITD positive AML. Furthermore, pharmacokinetic analyses revealed clinically important interactions between potent CYP3A4 inhibitors, such as azoles, and midostaurin. Aims To evaluate the pharmacodynamic activity of midostaurin measured as inhibition of the degree of phosphorylated FLT3 (pFLT3) in correlation to co-medication and outcome data. Methods The study includes intensively treated adults (age 18-70 years) with newly diagnosed FLT3-ITD positive AML enrolled in the ongoing single-arm phase-II AMLSG 16-10 trial (NCT: NCT01477606). Pts with acute promyelocytic leukemia are not eligible. The presence of FLT3-ITD is analyzed by Genescan-based fragment-length analysis (allelic ratio >0.05 required to be FLT3-ITD positive). Induction therapy consists of daunorubicin (60 mg/m², d1-3) and cytarabine (200 mg/m², continuously, d1-7); midostaurin 50 mg twice daily is applied from day 8 onwards until 48h before start of the next treatment cycle. For consolidation therapy, pts proceed to allogeneic hematopoietic stem cell transplantation (HSCT) as first priority; if allogeneic HSCT is not possible pts receive three cycles of age-adapted high-dose cytarabine in combination with midostaurin from day 6 onwards. In all pts maintenance therapy for one year is intended. A total sample size of n=142 is planned to show an improvement in event-free survival from 25% after 2 years to 37.5%. Plasma inhibitory activity assay (PIA) for pFLT3 is performed as previously described (Levis MJ, et al. Blood 2006; 108:3477-83). For PIA, measured time points include day 15 of induction therapy, the end of each treatment cycle and every three months during maintenance therapy. Results To date, 72 pts (median age, 54.5 years; range, 29-69 years) have been included and PIA was performed so far in 37 pts during induction therapy. Median pFLT3 inhibition after one week of midostaurin intake measured on day 15 of cycle 1 (C1D15) was 57.5% (range, 14.2-93.7%) with 2 of 31 pts showing inhibition >85%. At the end of the first induction cycle (C1end), median inhibition was 60.3% (range, 0-99.8%); here, 6 of 37 pts had an inhibition >85%. Co-medication with azoles was present in 7 of 23 pts at C1D15 and 13 of 28 pts at C1end. There was no significant difference in pFLT3 inhibition either on C1D15 (p=0.79) or at C1end (p=0.70) between pts on (median pFLT3 inhibition: 52.5%) or off (median pFLT3 inhibition 57.5%) azoles. Response data were available in 56 pts: complete remission (CR) was achieved in 78.5%; rates of early death and refractory disease (RD) were 9% and 12.5%, respectively. In first analyses, there was no difference in pFLT3 inhibition in pts achieving CR (n=30) as compared to those with RD (n=3; p=0.99). In contrast to our previously published data from three historical trials without a FLT3 inhibitor which showed that high allelic ratio was associated with low CR rates (Kayser S, et al. Blood 2009;114:2386-92), in the current trial CR rates remained high (81.5%) despite of a high allelic ratio above the median (>0.58). In addition, we did not see a negative prognostic impact of ITD insertion site within the tyrosine kinase domain of the FLT3 gene (p=0.99). Analyses are currently ongoing, measurement of FLT3 ligand levels and evaluation of pharmacokinetics of midostaurin are also intended. Conclusions The addition of 50 mg midostaurin twice daily to intensive induction therapy resulted in a moderate pFLT3 inhibition during induction therapy. Nonetheless, CR rates are promising, especially in pts with unfavorable FLT3-ITD characteristics. Concomitant azoles do not appear to significantly influence pFLT3 inhibitory activity of midostaurin. Disclosures: Levis: Ambit Biosciences: Consultancy. Schlenk:Ambit: Honoraria; Chugai: Research Funding; Novartis: Research Funding; Pfizer: Research Funding; Amgen: Research Funding." @default.
- W2470901114 created "2016-07-22" @default.
- W2470901114 creator A5003992313 @default.
- W2470901114 creator A5005056245 @default.
- W2470901114 creator A5006609689 @default.
- W2470901114 creator A5013231760 @default.
- W2470901114 creator A5013435653 @default.
- W2470901114 creator A5017172335 @default.
- W2470901114 creator A5018576827 @default.
- W2470901114 creator A5022563226 @default.
- W2470901114 creator A5026255080 @default.
- W2470901114 creator A5028771923 @default.
- W2470901114 creator A5029448872 @default.
- W2470901114 creator A5030025370 @default.
- W2470901114 creator A5030332519 @default.
- W2470901114 creator A5031540176 @default.
- W2470901114 creator A5032138074 @default.
- W2470901114 creator A5037133740 @default.
- W2470901114 creator A5039994927 @default.
- W2470901114 creator A5046469980 @default.
- W2470901114 creator A5053578678 @default.
- W2470901114 creator A5053949970 @default.
- W2470901114 creator A5054452324 @default.
- W2470901114 creator A5054636757 @default.
- W2470901114 creator A5058195823 @default.
- W2470901114 creator A5066679073 @default.
- W2470901114 creator A5073388713 @default.
- W2470901114 creator A5074468239 @default.
- W2470901114 creator A5075412542 @default.
- W2470901114 creator A5081614049 @default.
- W2470901114 creator A5081804029 @default.
- W2470901114 creator A5083170898 @default.
- W2470901114 creator A5084039929 @default.
- W2470901114 creator A5087312079 @default.
- W2470901114 date "2013-11-15" @default.
- W2470901114 modified "2023-09-30" @default.
- W2470901114 title "Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial" @default.
- W2470901114 doi "https://doi.org/10.1182/blood.v122.21.1283.1283" @default.
- W2470901114 hasPublicationYear "2013" @default.
- W2470901114 type Work @default.
- W2470901114 sameAs 2470901114 @default.
- W2470901114 citedByCount "3" @default.
- W2470901114 countsByYear W24709011142017 @default.
- W2470901114 countsByYear W24709011142018 @default.
- W2470901114 countsByYear W24709011142022 @default.
- W2470901114 crossrefType "journal-article" @default.
- W2470901114 hasAuthorship W2470901114A5003992313 @default.
- W2470901114 hasAuthorship W2470901114A5005056245 @default.
- W2470901114 hasAuthorship W2470901114A5006609689 @default.
- W2470901114 hasAuthorship W2470901114A5013231760 @default.
- W2470901114 hasAuthorship W2470901114A5013435653 @default.
- W2470901114 hasAuthorship W2470901114A5017172335 @default.
- W2470901114 hasAuthorship W2470901114A5018576827 @default.
- W2470901114 hasAuthorship W2470901114A5022563226 @default.
- W2470901114 hasAuthorship W2470901114A5026255080 @default.
- W2470901114 hasAuthorship W2470901114A5028771923 @default.
- W2470901114 hasAuthorship W2470901114A5029448872 @default.
- W2470901114 hasAuthorship W2470901114A5030025370 @default.
- W2470901114 hasAuthorship W2470901114A5030332519 @default.
- W2470901114 hasAuthorship W2470901114A5031540176 @default.
- W2470901114 hasAuthorship W2470901114A5032138074 @default.
- W2470901114 hasAuthorship W2470901114A5037133740 @default.
- W2470901114 hasAuthorship W2470901114A5039994927 @default.
- W2470901114 hasAuthorship W2470901114A5046469980 @default.
- W2470901114 hasAuthorship W2470901114A5053578678 @default.
- W2470901114 hasAuthorship W2470901114A5053949970 @default.
- W2470901114 hasAuthorship W2470901114A5054452324 @default.
- W2470901114 hasAuthorship W2470901114A5054636757 @default.
- W2470901114 hasAuthorship W2470901114A5058195823 @default.
- W2470901114 hasAuthorship W2470901114A5066679073 @default.
- W2470901114 hasAuthorship W2470901114A5073388713 @default.
- W2470901114 hasAuthorship W2470901114A5074468239 @default.
- W2470901114 hasAuthorship W2470901114A5075412542 @default.
- W2470901114 hasAuthorship W2470901114A5081614049 @default.
- W2470901114 hasAuthorship W2470901114A5081804029 @default.
- W2470901114 hasAuthorship W2470901114A5083170898 @default.
- W2470901114 hasAuthorship W2470901114A5084039929 @default.
- W2470901114 hasAuthorship W2470901114A5087312079 @default.
- W2470901114 hasConcept C104317684 @default.
- W2470901114 hasConcept C126322002 @default.
- W2470901114 hasConcept C143998085 @default.
- W2470901114 hasConcept C2776481607 @default.
- W2470901114 hasConcept C2776601000 @default.
- W2470901114 hasConcept C2776694085 @default.
- W2470901114 hasConcept C2777408962 @default.
- W2470901114 hasConcept C2778041864 @default.
- W2470901114 hasConcept C2778283404 @default.
- W2470901114 hasConcept C2778729363 @default.
- W2470901114 hasConcept C2781121885 @default.
- W2470901114 hasConcept C2910954276 @default.
- W2470901114 hasConcept C2911091166 @default.
- W2470901114 hasConcept C501734568 @default.
- W2470901114 hasConcept C55493867 @default.
- W2470901114 hasConcept C71924100 @default.
- W2470901114 hasConcept C86803240 @default.
- W2470901114 hasConcept C98274493 @default.
- W2470901114 hasConceptScore W2470901114C104317684 @default.
- W2470901114 hasConceptScore W2470901114C126322002 @default.